Thrombosis and cancer (Q56339353)

1

0 references

Oliver Chapman

2

0 references

Carole Connor

3

0 references

Christopher Poole

4

0 references

Peter Rose

5

0 references

Ajay K. Kakkar

Nature Reviews Clinical Oncology

6

0 references

language of work or name

English

0 references

publication date

10 July 2012

0 references

published in

0 references

volume

9

0 references

issue

8

0 references

page(s)

437-449

0 references

cites work

Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Cancer, clots and consensus: new understanding of an old problem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Incidence of venous thromboembolism in patients hospitalized with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Thromboembolism in hospitalized neutropenic cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Assessing risk of venous thromboembolism in the patient with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Tissue factor, angiogenesis and tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Mechanisms of disease: the impact of antithrombotic therapy in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Mechanisms of thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Genetic link between cancer and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Tissue factor and cell signalling in cancer progression and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Role of tissue factor in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Procoagulant microparticles: disrupting the vascular homeostasis equation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Leptin upregulates tissue factor expression in human breast cancer MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Cancer and the prothrombotic state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Malignancy, thrombosis and Trousseau: the case for an eponym.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Dysregulated expression of both the costimulatory CD28 and inhibitory CTLA-4 molecules in PB T cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Mechanisms of adverse effects of anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Incidence of venous thromboembolism and the impact on survival in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Hospital mortality due to pulmonary embolism and an evaluation of the usefulness of preventative interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Chronic thromboembolic pulmonary hypertension (CTEPH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Impact of venous thromboembolism, venous stasis syndrome, venous outflow obstruction and venous valvular incompetence on quality of life and activities of daily living: A nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Development and validation of a predictive model for chemotherapy-associated thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Venous thromboembolism in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Chemotherapy-induced thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the Nationa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Prediction of venous thromboembolism in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Prevention of venous thromboembolism in the cancer surgical patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Low-molecular-weight heparin and mortality in acutely ill medical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

The effect of low molecular weight heparin on survival in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Oral rivaroxaban for symptomatic venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Management of venous thromboembolism in cancer patients: ESMO clinical recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Upper-extremity deep vein thrombosis: a prospective registry of 592 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Venous thrombosis in cancer patients: insights from the FRONTLINE survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Microparticle-associated tissue factor activity: a link between cancer and thrombosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Prognosis of Cancers Associated with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

The MET oncogene drives a genetic programme linking cancer to haemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Deep-vein thrombosis and the incidence of subsequent symptomatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Tissue factor expression correlates with histological grade in human pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Outcomes and cost of deep venous thrombosis among patients with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Venous thromboembolism and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Risk factors for cancer-associated venous thromboembolism in outpatient deep venous thrombosis clinics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

High D-dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Venous thromboembolism in patients with active cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Routine heparin for patients with cancer? One answer, more questions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Microparticle-associated tissue factor activity in cancer patients with and without thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Risk factors for venous thromboembolic events in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.106

Variation in relative risk of venous thromboembolism in different cancers

31 March 2020

1 reference

12 December 2020

Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters

1 reference

12 December 2020

Incidence of venous thromboembolism and its effect on survival among patients with common cancers

1 reference

12 December 2020

Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells

1 reference

12 December 2020

Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality.

1 reference

12 December 2020

Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation

1 reference

12 December 2020

First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.

1 reference

12 December 2020

Low-molecular-weight heparin in the management of Tyrousseau's syndrome

1 reference

12 December 2020

Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism

1 reference

12 December 2020

Venous thrombosis in patients with solid tumors: determination of frequency and characteristics

1 reference

12 December 2020

Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer

1 reference

12 December 2020

Tissue factor expression in human leukocytes and tumor cells

1 reference

12 December 2020

Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis

1 reference

12 December 2020

Clotting mechanisms and cancer: implications in thrombus formation and tumor progression.

1 reference

12 December 2020

Prevention and treatment of venous thromboembolism and pulmonary embolism: the role of novel oral anticoagulants

1 reference

12 December 2020